protective effect of simvastatin for renal function in diabetic nephropathies

AIM: To probe the efficacy of simvastatin for lowering lipidemia in diabetic nephropathy with hyperlipidemia and protecting renal function. METHODS: Diabetic nephropathy with hyperlipidemia and chronic renal function lesion (n = 54) were randomly assigned two groups. Simvastatin group (M16,F14;age 54 a+- s 13 a) received simvastatin 10 mg, po, qd for 48 wk, in addition to conventional therapy (benazepril 10 mg, po, qd and dipyridamole 50 mg, to, tid). Control group (M10, F14; age 54 a +- 12 a) were treated with the same conventional therapy mentioned abave. RESULTS: The improvements of serum cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, proteinuria, serum creatinine and endogenous creatinine clearance in simvastatin group were superior to those in the control group(P 0.01 ). CONCLUSION: Simvastatin can decrease lipidemia, associated to the proteinuria decrease and the protection of renal function.